In 2016, the Stop TB Partnership and Otsuka announced an innovative public-private partnership to enable all countries eligible for financing TB activities through the Global Fund to access delamanid through the Global Drug Facility.
Delamanid is approved by a stringent regulatory authority (European Medicines Agency [EMA] and Japan).
Please see the latest guidelines and rapid communications from the WHO Global TB Programme for more information on the role of delamanid in the treatment of TB.
If you need to report an adverse event related to delamanid, please follow the instructions here.
If you have any additional questions related to ordering delamanid, please address your inquiries to your Country Support Officer or gdf@stoptb.org
Results of Global Drug Facilitiy´s 2024 Tender for Delamanid